Searching for COVID-19 treatments: First, do no harm
Guharoy, Roy ; Krenzelok, Edward
Citations
Authors
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Subject Area
Collections
Embargo Expiration Date
Link to Full Text
Abstract
FDA is the gatekeeper to protect the public health and is critical to sustain US global leadership in drug innovation. Our foundation of evidence-based clinical practice is based on large, well-designed randomized controlled trials. The failure of HCQ against COVID-19 stands as prime example of the urgent need for adherence to science. Rigorous scientific objectivity Downloaded from https://academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxaa257/5879960 by Medical Center Library user on 17 August 2020 13 and independence must prevail in any future EUA decision by FDA. Trust in FDA’s mission to approve safe and effective medications was built over decades by the capable scientists working for the agency, and the integrity of public trust must be protected to conquer future pandemics and ensure safe use of vaccines against COVID-19 once they become available.
Source
Guharoy R, Krenzelok E. Searching for COVID-19 treatments: First, do no harm. Am J Health Syst Pharm. 2020 Aug 3:zxaa257. doi: 10.1093/ajhp/zxaa257. Epub ahead of print. PMID: 32744592. Link to article on publisher's site